Yunfeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yunfeng Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bo Lu
Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
1 shared publication Da Li
Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
1 shared publication- Deyu Fu
Deyu Fu, PhD, MD, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, China
1 shared publication Jianhua Li
Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
1 shared publicationLei Yao
Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
1 shared publicationMingtai Gui
Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 4911-4932
A Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes
The global epidemic of obesity and diabetes imposes a significant strain on healthcare systems, substantially elevating the risk of vascular dysfunction and its associated complications. Astragaloside IV (AS-IV) and berberine (BBR) have demonstrated considerable promise in addressing vascular issues linked to these conditions. This review examines the mechanisms driving their vascular protective effects, drawing on evidence from preclinical studies to compare and contrast their modes of action. It explores both the unique and overlapping pathways through which they mitigate the complications of obesity and diabetes. A thorough analysis of their therapeutic potential highlights promising preclinical data and its clinical implications. However, challenges remain, such as enhancing the bioavailability of AS-IV and BBR and translating preclinical findings into robust clinical trials. This synthesis provides critical insights for advancing research and practical approaches in managing vascular dysfunction associated with obesity and diabetes.
- 1 June 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 4911-4932
Open AccessA Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes
The global epidemic of obesity and diabetes imposes a significant strain on healthcare systems, substantially elevating the risk of vascular dysfunction and its associated complications. Astragaloside IV (AS-IV) and berberine (BBR) have demonstrated considerable promise in addressing vascular issues linked to these conditions. This review examines the mechanisms driving their vascular protective effects, drawing on evidence from preclinical studies to compare and contrast their modes of action. It explores both the unique and overlapping pathways through which they mitigate the complications of obesity and diabetes. A thorough analysis of their therapeutic potential highlights promising preclinical data and its clinical implications. However, challenges remain, such as enhancing the bioavailability of AS-IV and BBR and translating preclinical findings into robust clinical trials. This synthesis provides critical insights for advancing research and practical approaches in managing vascular dysfunction associated with obesity and diabetes.